Items Tagged ‘HNL’

May 4th, 2017

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma


Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76% of patients with Diffuse Large B-Cell Lymphoma (DLBCL) responded to treatment, 47% achieving a complete remissions (CR). About axicabtagene ciloleucel Axicabtagene […]

View full entry

Tags: CAR T, HD, HNL, immunotherapy, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma